Read by QxMD icon Read

ius levonorgestrel

Courtney A Schreiber, Stephanie B Teal, Paul D Blumenthal, Lisa M Keder, Andrea I Olariu, Mitchell D Creinin
PURPOSE: Evaluate bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system (IUS) using the World Health Organization Belsey definitions. MATERIAL AND METHODS: This prospective multicenter trial evaluates the efficacy and safety of Liletta® ( NCT00995150). We evaluated bleeding patterns for 1700 nulliparous and multiparous women using a daily diary completed by participants for the first 2 years and by questionnaire every 3 months thereafter...
March 21, 2018: European Journal of Contraception & Reproductive Health Care
Riina Korjamo, Oskari Heikinheimo, Maarit Mentula
OBJECTIVE: To analyse the post-abortion effect of long-acting reversible contraception (LARC) plans and initiation on the risk of subsequent unwanted pregnancy and abortion. MATERIALS AND METHODS: retrospective cohort study of 666 women who underwent medical abortion between January-May 2013 at Helsinki University Hospital, Finland. Altogether 159 (23.8%) women planning post-abortion use of levonorgestrel-releasing intrauterine system (LNG-IUS) participated in a randomized study and had an opportunity to receive the LNG-IUS free-of-charge from the hospital...
March 14, 2018: European Journal of Contraception & Reproductive Health Care
S Geoffron, J Cohen, M Sauvan, G Legendre, J M Wattier, E Daraï, H Fernandez, N Chabbert-Buffet
The available literature, from 2006 to 2017, on hormonal treatment has been analysed as a contribution to the HAS-CNGOF task force for the treatment of endometriosis. Available data are heterogeneous and the general level of evidence is moderate. Hormonal treatment is usually offered as the primary option to women suffering from endometriosis. It cannot be used in women willing to conceive. In women who have not been operated, the first line of hormonal treatment includes combined oral contraceptives (COC) and the levonorgestrel-releasing intra uterine system (52mg LNG-IUS)...
March 10, 2018: Gynecologie, Obstetrique, Fertilite & Senologie
M Sauvan, N Chabbert-Buffet, M Canis, P Collinet, X Fritel, S Geoffron, G Legendre, J-M Wattier, H Fernandez
OBJECTIVE: To provide clinical practice guidelines for the management of painful endometriosis in women without infertility. METHODS: Systematic review of the literature literature since 2006, level of evidence rating, external proofreading and grading of the recommendation grade by an expert group according to HAS methodology. RESULTS: Combined hormonal contraceptives (COP) and the levonorgestrel-releasing intra-uterin system (LNG-IUS) are recommended as first-line hormonal therapies for the treatment of painful endometriosis (grade B)...
March 3, 2018: Gynecologie, Obstetrique, Fertilite & Senologie
Meiqiu Lu, Xin Yang
BACKGROUND: Glanzmann's Thrombasthenia (GT) is an inherited genetic disorder caused by defects in the platelet membrane glycoproteins IIb/IIIA, and is associated with heavy menstrual bleeding (HMB). HMB is a common complication in female patients, and many adolescent girls with this disease have issues with HMB beginning at menarche. The available treatment modalities including anti-fibrinolytics, nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies though are effective, their associated side effects, limited efficacy and the poor compliance is a challenge in management of HMB...
February 27, 2018: BMC Women's Health
Wojciech Wrona, Anna Stępniak, Piotr Czuczwar
Uterine fibroids are considered to be the most frequently occurring tumours in females. The majority of fibroids do not require any treatment. When symptomatic, the major ailments include abnormal uterine bleeding, painful menstruation, pelvic pressure or pain, urinary problems, constipation, infertility, and recurrent pregnancy loss. Surgery remains a mainstay of symptomatic uterine fibroids therapy; however, minimally-invasive techniques and pharmacological management have become more available. The levonorgestrel intrauterine system (LNG-IUS) is a T-shaped device with a vertical stem containing a reservoir of levonorgestrel and is widely known for its contraception effect...
December 2017: Przeglad Menopauzalny, Menopause Review
Mie Jareid, Jean-Christophe Thalabard, Morten Aarflot, Hege M Bøvelstad, Eiliv Lund, Tonje Braaten
OBJECTIVE: Women with ovarian cancer have poor survival rates, which have proven difficult to improve; therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-IUS. METHODS: Our study cohort consisted of 104,318 women from the Norwegian Women and Cancer Study, 9144 of whom were ever users and 95,174 of whom were never users of LNG-IUS...
February 23, 2018: Gynecologic Oncology
K M Sinning, D C Jude, J L Yoost
STUDY OBJECTIVE: To quantify the "normal" adolescent experience after IUD insertion, in order to provide appropriate counseling for future adolescents. DESIGN: Prospective cohort study. SETTING: Marshall University Department of Obstetrics and Gynecology generalist and adolescent gynecology clinics. PARTICIPANTS: Nulliparous adolescents age 13-18 and parous adults ≥18 years receiving a levonorgestrel intrauterine system (LNG-IUS)...
February 17, 2018: Journal of Pediatric and Adolescent Gynecology
Ching-Jung Lin, Teh-Fu Hsu, Yen-Hou Chang, Ben-Shian Huang, Ling-Yu Jiang, Peng-Hui Wang, Yi-Jen Chen
OBJECTIVE: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. MATERIALS AND METHODS: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria...
February 2018: Taiwanese Journal of Obstetrics & Gynecology
Gilbert Gerard Ghislain Donders, G Bellen, Kateryna Ruban, Ben Van Bulck
BACKGROUND: Recurrent vulvovaginal infections are a frequent complaint in young women in need of contraception. However, the influence of the contraceptive method on the course of the disease is not well known. AIM: To investigate the influence of the levonorgestrel-releasing intrauterine-system (LNG-IUS) on the vaginal microflora. METHODS: Short-term (3 months) and long-term (1 to 5 years) changes of vaginal microbiota were compared with pre-insertion values in 252 women presenting for LNG-IUS insertion...
January 29, 2018: Journal of Medical Microbiology
(no author information available yet)
A levonorgestrel (LNG) intrauterine system (IUS) known as Kyleena (Bayer PLC) received marketing authorisation from the European Medicines Agency in 2016.1 The device contains 19.5mg LNG and is licensed for contraception for up to 5 years. This is the fourth LNG IUS product to be licensed for use in the UK. The company states that Kyleena offers advantages over Mirena and Jaydess LNG IUS devices.2 Here we consider the evidence for Kyleena.
February 2018: Drug and Therapeutics Bulletin
Salvatore Caruso, Stefano Cianci, Salvatore Giovanni Vitale, Valentina Fava, Silvia Cutello, Antonio Cianci
PURPOSE: The aim of the study was to investigate the impact of the long-acting reversible contraception (LARC) levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) on sexual function and quality of life (QoL) in women after having undergone abortion for unintended pregnancy. METHODS: In a prospective controlled study, 128 women aged 16-35 years received counseling to adopt LNG-IUS contraception after termination of pregnancy. The Visual Analog Scale (VAS), the Short Form-36 questionnaire (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to investigate, respectively, pelvic pain levels, QoL, sexual function and sexual distress of these women at baseline (T0) and at 6 (T1) and 12 (T2) months after LNG-IUS placement...
February 13, 2018: European Journal of Contraception & Reproductive Health Care
Christophe Vayssière, Adrien Gaudineau, Luisa Attali, Karima Bettahar, Sophie Eyraud, Philippe Faucher, Patrick Fournet, Danielle Hassoun, Marie Hatchuel, Christian Jamin, Brigitte Letombe, Teddy Linet, Marie Msika Razon, Alexandra Ohanessian, Hélène Segain, Solène Vigoureux, Norbert Winer, Sophie Wylomanski, Aubert Agostini
The number of elective abortions has been stable for several decades. Many factors explain women's choice of abortion in cases of unplanned pregnancies. Early initiation of contraceptive use and a choice of contraceptive choices appropriate to the woman's life are associated with lower rates of unplanned pregnancies. Reversible long-acting contraceptives should be favored as first-line methods for adolescents because of their effectiveness (grade C). Ultrasound scan before an elective abortion must be encouraged but should not be obligatory (professional consensus)...
March 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
C M McCarthy, C B Burke
We conducted a retrospective postal questionnaire-based study to assess the effectiveness and patient experience of minimally invasive treatments for menorrhagia by performing a two- to five-year follow up of patient symptoms. Questionnaires were distributed to 111 and 117 women following thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS), with response rates of 58.5% and 43.6% respectively. Sanitary pad use during the heaviest day of bleeding reduced by 8.4 and 5.2 pads in the TBEA and LNG-IUS groups respectively (p<0...
September 18, 2017: Irish Medical Journal
Kevin Cooper, Kirsty McCormack, Suzanne Breeman, Jessica Wood, Neil W Scott, Justin Clark, Jed Hawe, Robert Hawthorn, Kevin Phillips, Angela Hyde, Alison McDonald, Mark Forrest, Samantha Wileman, Graham Scotland, John Norrie, Siladitya Bhattacharya
BACKGROUND: Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®)...
January 24, 2018: Trials
Nese Yucel, Erdem Baskent, Burcin Karamustafaoglu Balci, Gokhan Goynumer
BACKGROUND AND AIMS: The aim of this study was to investigate the effectiveness of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic relief of pain in women with endometriosis and additionally, to assess the changes in women's life quality and serum cancer antigen (CA) 125 levels. MATERIALS AND METHODS: All women who had an LNG-IUS inserted for the treatment of dysmenorrhea, chronic pelvic pain or both for more than six months over a two-year period were included in the study...
January 23, 2018: Australian & New Zealand Journal of Obstetrics & Gynaecology
Reuben M Valenzuela, Ruju Rai, Brian H Kirk, Jessica N Sanders, Subhashree Sundar, Steffen Hamann, Judith E A Warner, Kathleen B Digre, Alison V Crum, Kirtly P Jones, Bradley J Katz
Because of a previous association of pseudotumor cerebri (PTC) with levonorgestrel, we wished to evaluate the use of levonorgestrel-eluting intrauterine devices ("levonorgestrel intrauterine systems", LNG-IUS) in our University of Utah and Rigshospitalet PTC patients. In our retrospective series, PTC prevalence was approximately 0.18% and 0.15% in the LNG-IUS population versus 0.02% and 0.04% in the non-LNG-IUS population (Utah and Rigshospitalet, respectively), with no significant differences in PTC signs and symptoms among the two groups...
August 2017: Neuro-ophthalmology
Mohamed Rezk, Alaa Al-Halaby, Mohamed Emarh, Mohamed Shawky
No abstract text is available yet for this article.
January 12, 2018: European Journal of Contraception & Reproductive Health Care
Mohamed Rezk, Tarek Sayyed, Alaa Masood, Ragab Dawood
No abstract text is available yet for this article.
January 11, 2018: European Journal of Contraception & Reproductive Health Care
Clare Barnett, Sabine Moehner, Thai Do Minh, Klaas Heinemann
OBJECTIVES: The objective of this analysis was to identify intra-uterine devices (IUD) perforations detected from 12 to 60 months following IUD insertion, and to combine this information with (our previously published) data about perforations detected in the first 12 months to calculate cumulative perforation rates. METHODS AND MATERIALS: Prospective, non-interventional cohort study with new users of levonorgestrel-releasing intra-uterine systems (LNG-IUS) and copper-IUD...
January 11, 2018: European Journal of Contraception & Reproductive Health Care
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"